Other OTC - Delayed Quote USD

Avenir Wellness Solutions, Inc. (AVRW)

0.0439 +0.0052 (+13.29%)
At close: May 17 at 1:23 PM EDT
Loading Chart for AVRW
DELL
  • Previous Close 0.0388
  • Open 0.0332
  • Bid --
  • Ask --
  • Day's Range 0.0330 - 0.0439
  • 52 Week Range 0.0230 - 0.2500
  • Volume 15,167
  • Avg. Volume 21,022
  • Market Cap (intraday) 3.214M
  • Beta (5Y Monthly) -0.46
  • PE Ratio (TTM) --
  • EPS (TTM) -0.1500
  • Earnings Date Jul 26, 2024 - Jul 30, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Avenir Wellness Solutions, Inc., through its subsidiary The Sera Labs, Inc., engages in the development of nutraceutical formulation and delivery technologies in novel dosage forms to improve efficacy and enhance wellness. It provides its products in beauty, health and wellness, and pet care categories under the Seratopical, Seratopical Revolution SeraLabs, and Nutri-Strips brand names. The company sells its products through drug and grocery chains, convenience stores, and mass retailers. It also offers its products under private label to retailers and multi-level marketers, as well as DTC, via online website orders. The company was formerly known as CURE Pharmaceutical Holding Corp. and changed its name to Avenir Wellness Solutions, Inc. in October 2022. Avenir Wellness Solutions, Inc. was founded in 2011 and is headquartered in Sherman Oaks, California.

www.avenirwellness.com

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: AVRW

Performance Overview: AVRW

Trailing total returns as of 5/17/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

AVRW
40.68%
S&P 500
11.18%

1-Year Return

AVRW
67.96%
S&P 500
29.04%

3-Year Return

AVRW
93.77%
S&P 500
27.06%

5-Year Return

AVRW
98.76%
S&P 500
84.38%

Compare To: AVRW

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: AVRW

Valuation Measures

Annual
As of 5/17/2024
  • Market Cap

    3.21M

  • Enterprise Value

    11.53M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.76

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    2.79

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -255.34%

  • Return on Assets (ttm)

    -50.00%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    4.14M

  • Net Income Avi to Common (ttm)

    -10.56M

  • Diluted EPS (ttm)

    -0.1500

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    189k

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -1.58M

Research Analysis: AVRW

Company Insights: AVRW

Research Reports: AVRW

People Also Watch